Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05421663 · ClinicalTrials.gov registry record · Phase 1
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
A Phase 1 study of Lymphoma, Non-Hodgkin and Lymphoma, B-Cell, sponsored by Janssen Research & Development.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 439
- Enrollment target
- 20
- Study locations
NCT05421663 is a Phase 1 study of Lymphoma, Non-Hodgkin and Lymphoma, B-Cell that is actively recruiting participants, run by Janssen Research & Development. The registered enrollment target is 439 participants, above the 386-participant average among 56 other Lymphoma, Non-Hodgkin trials with a reported enrollment target (14% higher). The trial reports 20 study locations across 13 states.
The verdict
NCT05421663, a Phase 1 study of Lymphoma, Non-Hodgkin and Lymphoma, B-Cell, is actively recruiting participants, sponsored by Janssen Research & Development.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 439 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 1b/2, multicenter, open-label, study of prizloncabtagene autoleucel (prizlo-cel), an autologous dual targeting chimeric antigen receptor (CAR) T-cell therapy targeting both cluster of differentiation (CD) CD20 and CD19, for the treatment of adult participants with relapsed or refractory (r/r) B-Cell non-Hodgkin lymphoma (B-NHL) or frontline high-risk diffuse large B-cell lymphoma (DLBCL).
Conditions Studied
Interventions
- BIOLOGICAL Prizloncabtagene autoleucel (Prizlo-Cel)
Study Locations (20)
Other
- St Vincents Hospital Melbourne - Fitzroy
- The Alfred Hospital - Melbourne
- Fiona Stanley Hospital - Murdoch
- Calvary Mater Newcastle Hospital - Waratah
- Rigshospitalet - Copenhagen
- Odense University Hospital - Odense
Tennessee
- Greco Hainesworth Tennessee Oncology Centers for Research - Nashville
- Sarah Cannon Research Institute - Nashville
Texas
- St. David's South Austin Medical Center - Austin
- Texas Transplant Institute - San Antonio
California
- City of Hope - Duarte
Colorado
- Colorado Blood Cancer Institute - Denver
Iowa
- University of Iowa Hospital and Clinics - Iowa City
Kentucky
- University of Kentucky Medical Center - Lexington
New Jersey
- Rutgers Cancer Institute of New Jersey - Piscataway
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 439 participants |
| Start Date | 2022-08-12 |
| Est. Completion | 2029-03-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05421663
The ClinicalTrials.gov registry entry for NCT05421663 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 439 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 386-participant average among 56 other Lymphoma, Non-Hodgkin trials with a reported enrollment target (14% higher). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Lymphoma, Non-Hodgkin appearing as the primary indexed condition, and to 1 intervention - of which Prizloncabtagene autoleucel (Prizlo-Cel) is the first listed.
NCT05421663 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Other, Tennessee, Texas.
Frequently Asked Questions
What is clinical trial NCT05421663 about?
NCT05421663 is a clinical study titled "A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma". This is a Phase 1b/2, multicenter, open-label, study of prizloncabtagene autoleucel (prizlo-cel), an autologous dual targeting chimeric antigen receptor (CAR) T-cell therapy targeting both cluster of differentiation (CD) CD20 and CD19, for the treatment of adult participants with relapsed or refract...
What is the current status of trial NCT05421663?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 439 participants. The study started on 2022-08-12. Estimated completion is 2029-03-12.
What conditions does trial NCT05421663 study?
This clinical trial studies the following conditions: Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse.
What interventions are being tested in trial NCT05421663?
The interventions under investigation include: Prizloncabtagene autoleucel (Prizlo-Cel) (BIOLOGICAL).
Who is sponsoring clinical trial NCT05421663?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05421663 being conducted?
This trial has 20 study locations across California, Colorado, Iowa, Kentucky, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma, Non-Hodgkin
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
RECRUITING · Phase 1
-
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
RECRUITING · Phase 1
-
Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.